| 235 | Jennifer Sims-Mourtada, Ph.D. | <p>​Senior Clinical Scientist, Center for Translational Cancer Research, Helen F. Graham Cancer Center,<br></p>
<p>Affiliated Faculty, Department of Biological Sciences, University of Delaware, Newark, DE. </p> | (302) 623-4648 | | jsimsmourtada@christianacare.org | Center for Translational Cancer Research, Helen F. Graham Cancer Center, | | Newark, DE | <p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">2004 - Ph.D. in Biomedical Sciences, Department of Immunology, The University of </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">Texas Graduate School of Biomedical Sciences. Houston, Texas.</font></font></p>
<p align="left"><b><i><font size="3" face="Helvetica-BoldOblique"><font size="3" face="Helvetica-BoldOblique">Doctoral Dissertation:</font></font></i></b><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Â </font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">Studies on Gene Expression within Germinal Centers</font></font></p>
<p align="left"><b><i><font size="3" face="Helvetica-BoldOblique"><font size="3" face="Helvetica-BoldOblique">Advisor: </font></font></i></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">Hector Martinez-Valdez, M.D., Ph.D., The University of Texas M.D.</font></font></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">Anderson Cancer Center.</font></font></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">1995 - Bachelor of Arts in Psychology. The University of Texas at Austin, Austin,</font></font></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">Texas.</font></font></p>
<p align="left"><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Post-Doctoral Training</font></font></b></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">2004-2006: Post-doctoral Fellow, Department of Experimental Radiation Oncology, The</font></font></p>
<p><font size="3" face="Helvetica"><font size="3" face="Helvetica">University of Texas M.D. Anderson Cancer Center, Houston, Texas</font></font></p> | | | <p><strong><u>Cancer stem cell signatures in hereditary and aggressive breast cancers</u></strong></p>
<p>Approximately 85% of women with germ-line mutations in the BRCA1 gene will eventually develop breast cancer. For these women, the only current preventative measure is bilateral mastectomy or oophorectomy The goal of this project is to find less invasive measures to prevent and treat cancer in this patient population. BRCA1 plays a role in differentiation of mammary stem cells as well as DNA repair. Loss of BRCA1 is thought to result in the accumulation of genetically unstable stem cells, leading to further carcinogenic events and the generation of cancer stem cells (CSC). Intrinsic features of CSC include the capacity for self-renewal, increased resistance to radiation and chemotherapy and the ability to induce tissue vascularization and invasion. These attributes suggest that CSC may be the principal driving force behind tumor growth, metastases and recurrence.</p>
<p>Several developmental pathways have been shown to regulate self-renewal and differentiation of mammary stem cells. These pathways, such as Hedgehog, WNT and Notch have been linked to tumorigenesis and are often activated in aggressive tumors. Inhibitors to these pathways are currently under clinical development by several major pharmaceutical companies. This project will identify stem cell pathways that are activated in tumor specimens from patients with BRCA1 mutations and examine the effects of targeted inhibition of these pathways on the growth and survival of breast cancer cell lines harboring BRCA1 mutations.</p>
<p>Â </p>
<p><strong><u>Radiation induced expansion of cancer stem cells</u></strong></p>
<p>Increased activation of the hedgehog pathway has been observed in cancer stem cells. Increased mRNA levels of SHH, Gli and the receptor PTCH-1 have been reported in CD44<sup>+</sup>CD24<sup>-/low</sup>/lin<sup>-</sup> breast cancer cells isolated from human tumors, compared to the bulk of tumor cells.  Our group has identified a higher expression of the PTCH receptor on the surface of breast cancer stem-like cells than the total cellular population in several breast cancer cell lines. Additionally, we have shown that breast cancer cells cultured in stem cell promoting conditions secrete higher levels of SHH. Previous studies by our group and others  have suggested  that there is an increase in cancer stem cells after exposure to radiation and chemotherapy. The goal of this project is to determine if hedgehog signaling contributes to the survival and proliferation of cancer stem cells after radiation treatment and how hedgehog interacts with other stem cell pathways that are activated under these conditions.  </p> | | <p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">1.Smith, D.L., Breeman, WAP, </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada, J</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">. The untapped potential of 68-Gallium-PET:</font></font></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">the next wave of 68-gallium agents. Journal of Applied Radiation and Isotopes, 2012, </font></font><font face="Helvetica">2012</font></p>
<p align="left"><font face="Helvetica">Oct 29 <a>(12)00537-4</a>.</font></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">2. </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada,J</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">. Yang,D., Tworowka, I, Larson, R, Smith, D, Tsao, N, Opdenaker, L.,</font></font></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">Mourtada, F. Woodward, W. Detection of canonical hedgehog signaling in breast cancer by</font></font></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">131-Iodine-labeled derivatives of the sonic hedgehog protein.</font></font></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Journal of Biomedicine and </font></font></i><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Biotechnology</font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">, 2012, Article ID </font></font><font face="Helvetica">639562</font><font size="3" face="Helvetica"><font size="3" face="Helvetica">.</font></font></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">3. Delpassand,E., Samarghandi,,A., </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims Mourtada,J, </font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">Zamanian,S ., Espanan,G., Sharif,R.,</font></font></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">MacKenzie,S., Kosari,K., Barakat, B., Naqvi,S.,Seng,JE., Lowell Anthony,L. Long-term</font></font></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">survival and toxicity profile of patients with progressive neuroendocrine tumors following</font></font></p>
<p align="left"><font size="3" face="Helvetica"><font size="3" face="Helvetica">Peptide Receptor Radionuclide Therapy with high activity </font></font><font size="1" face="Helvetica"><font size="1" face="Helvetica">111</font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">In pentetreotide </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">Theranostics,2012, </font></font><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">in press.</font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica">4. McKeller MR, Herrera-Rodriquez S, Ma W, Ortiz-Quintero, b, Rangel R, Cande C, </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-</font></font></b><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Mourtada</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">, J, Melinikova, V, Kashi C, Phan LM, Chen Z Huang P, Dunner K, Kroemer G,</font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">Singh KK, Martinez-Valdez, H. Vital function of PRELI and essential requirement of its LEA </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">motif. </font></font><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Cell Death and Disease</font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">, 2010 (1) 113.</font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica">5. Delpassand,E.S., </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada, J., </font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">Saso, H, Azhdarinia, A; Ashoori, F, Torabi, F.,</font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica">Espenan, G., Moore, W.H, Woltering, E. and Anthony, A. Safety and efficacy of radionuclide</font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica">therapy with multiple 500 mCi doses of In-111 Pentetreotide in patients with progressive</font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica">neuroendocrine tumors. </font></font><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Cancer Biotherapy and Radiopharmaceuticals</font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">, 2008, 23(3): 292-</font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">300.</font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica">6. </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada, J.</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">, Azhdarinia, A., Yang, D.J.., Mourtada, F. Regulatory Requirements for </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">PET Radiopharmaceuticals Production: Is Automation an Answer? </font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Current Molecular </font></font></i><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Imaging Reviews</font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">: 2008, 4(1): 28-33.</font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica">7. Yang, D.Y., Chandra, M., </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada, J.</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">, Azhdarinia, A., Oh,C.S., Kim, E. Challenges </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">and Opportunities in Molecular Imaging. </font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Current Molecular Imaging Reviews: </font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">2008 4(1) 46-</font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">50 .</font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica">8. </font></font><font color="#231f20" size="3" face="Helvetica"><font color="#231f20" size="3" face="Helvetica"><font color="#231f20" size="3" face="Helvetica">Izzo, JG., Luthra, R., </font></font></font><b><font color="#231f20" size="3" face="Helvetica-Bold"><font color="#231f20" size="3" face="Helvetica-Bold"><font color="#231f20" size="3" face="Helvetica-Bold">Sims-Mourtada, J, </font></font></font></b><font color="#231f20" size="3" face="Helvetica"><font color="#231f20" size="3" face="Helvetica"><font color="#231f20" size="3" face="Helvetica">Chao, KSC, Lee, JH, Wu, TT, Correa, AM, Luthra,</font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font color="#231f20" size="3" face="Helvetica"><font color="#231f20" size="3" face="Helvetica"><font color="#231f20" size="3" face="Helvetica">M, Aggarwal, B, Hung, MC, Ajani, A. Emerging Molecular Targets in Esophageal Cancer. </font></font></font><font color="#231f20" size="3" face="Helvetica"><font color="#231f20" size="3" face="Helvetica"><font color="#231f20" size="3" face="Helvetica">GastroIntestinal Cancer Research: 2007 1(4) S3-S6.</font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica">9. Chen, Y.J., </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada, J</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">., Izzo, J.G., Chao, KSC. Targeting the Hedgehog Pathway to </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">mitigate treatment resistance. Cell Cycle: 2007, 6(15):1826-30.</font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica">10. </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada,J., </font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">Izzo, J.G., Ajani, J.A., Chao, K.S.C. Sonic Hedgehog promotes multiple </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">drug resistance by regulation of drug transport, </font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Oncogene</font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">. 2007 Aug 16;26(38):5674-9.</font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica">11. </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada, J, </font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">Izzo, J.G., Apisarnthanarax,S., Wu, TT, Malhotra, U, Luthra,R., Liao, Z, </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">Komaki, R., van der Kogel, A., Ajani, J, Chao, K.S.C. Hedgehog: an attribute to tumor </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">regrowth after chemoradiotherapy and a target to improve radiation response. </font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Clinical </font></font></i><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Cancer Research. </font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">2006. Nov 1;12(21):6565-72.</font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">12. </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada, JC</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">, Guzman-Rojas, L. Rangel, R, McKellar,M, Gordon, J, Popescu, N.,</font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">Lopez, C., Bruce, S., Wilkinson, M. and Martinez-Valdez, H. The human AKNA gene maps to</font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">chromosome 9q32.1, expresses alternatively spliced transcripts and translates into </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">overlapping protein isoforms . </font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">DNA Cell Bio</font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">l. 24(5):325-38, (2005).</font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">13. Rangel, R, McKeller MR, </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada JC, </font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">Kashi C, Cain K, Wieder ED, Moldrem, JJ,</font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">Phan LV, Ford RJ, Yotnda, P, Guret C., Frances V, Martinez-Valdez H. Assemble of the k </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">PreB receptor requires the Vk- like protein encoded by germline transcripts. </font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">J Biol Chem. </font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">280(18):17807-14. (2005).</font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">14. </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada JC</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">, Guzman-Rojas L, Rangel R, Nghiem DX, Ullrich SE, Guret C, Cain K,</font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">Martinez-Valdez H. In vivo expression of interleukin-8, and RANTES by human germinal centre </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">B lymphocytes. Immunology. 110(3):296-303 (2003).</font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">15. Guzman-Rojas, L. </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">, </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">JC</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">, Rangel, R and Martinez-Valdez, H. Life and death </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">within germinal centers: a double-edged sword. </font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Immunology</font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">. 107:167-175. (2002)</font></font><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">.</font></font></i></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">16. Siddiqa, A. </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims-Mourtada, J</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">., Guzman-Rojas, L., Rangel, R., Guret, C., Madrid-Marina, V,</font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">Sun, Y. and Martinez-Valdez, H. Regulation of CD40 and CD40 ligand by the AT-hook </font></font><font size="3" face="Helvetica"><font size="3" face="Helvetica">transcription factor AKNA. </font></font></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Nature </font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">41: 383-387, (2001). </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Co-first author</font></font></b></font></font></font></font></i></p>
<p align="left"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">17. Guzman-Rojas L, </font></font><b><font size="3" face="Helvetica-Bold"><font size="3" face="Helvetica-Bold">Sims JC</font></font></b><font size="3" face="Helvetica"><font size="3" face="Helvetica">, Rangel R, Guret C, Sun Y, Alcocer JM, & Martinez-Valdez H.</font></font></font></font></font></font></i></p>
<p><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><font size="3" face="Helvetica">PRELI, the human homologue of the avian px19, is expressed by germinal center B <font size="3" face="Helvetica"><font size="3" face="Helvetica">lymphocytes. </font></font></font></font></font></font></font></font></i></p>
<p><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica"><font size="3" face="Helvetica"><i><font size="3" face="Helvetica-Oblique"><font size="3" face="Helvetica-Oblique">Int Immunol</font></font></i><font size="3" face="Helvetica"><font size="3" face="Helvetica">.12:607-12.(2000).</font></font></font></font></font></font></i></p>
<p>Â </p> | | | | |